Laurence Zitvogel

USPTO Granted Patents = 20 (Patent Applications = 9)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 25)

Average Co-Inventor Count = 2.6

ph-index = 6

Forward Citations = 84(Granted Patents)

Location History:

Antony, FR (2008 - 2013)
Paris, FR (2004 - 2023)

Company Filing History:

19 out of 95

Institut Gustave Roussy

patents

8 out of 1,743

Institut National De La Sante Et De La Recherche Medicale

patents

5 out of 78

Université Paris-Saclay

patents

4. 2 out of 40

Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement

patents

5. 1 out of 5,072

Centre National De La Recherche Scientifique

Institut De La Recherche Agronomique

patents

9. 1 out of 1

Centre Hospitalier Universitaire De Rennes

Institut National De La Sante Et De La Recherche Medicale (inserm)

patents

12. 1 out of 1

Insitut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement (inrae)

patent

13. 1 out of 832,718

Other

patents

where one patent can have more than one assignee

Years Active: 2004-2025

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12246044 - Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same (2025-03-11),

2. 12144839 - Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 AB-based treatment (2024-11-19),

3. 12102672 - Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancer (2024-10-01),

4. 11684640 - Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 ab-based (2023-06-27),

5. 11344586 - Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment (2022-05-31),

6. 10765710 - Combination of oncolytic virus with immune checkpoint modulators (2020-09-08),

7. 10646521 - Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment (2020-05-12),

8. 9810692 - Methods for predicting the sensitivity of a subject to immunotherapy (2017-11-07),

9. 9593376 - Natural killer p30 (NKp30) dysfunction and the biological applications thereof (2017-03-14),

10. 9557333 - Methods of treating gastrointestinal sarcoma patients depending on their sB7H6 serum level (2017-01-31),

11. 8865653 - Method of treatment for immunogenic treatment resistant cancer (2014-10-21),

12. 8828944 - Compounds and uses thereof to induce an immunogenic cancer cell death in a subject (2014-09-09),

13. 8557517 - Toll like receptor 4 dysfunction and the biological applications thereof (2013-10-15),

14. 8409813 - Treatment of cancer using TLR3 agonists (2013-04-02),

15. 8263344 - Compounds regulating calreticulin, KDEL receptor and/or Erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment (2012-09-11),

Title: The Innovative Mind of Laurence Zitvogel

Introduction: Laurence Zitvogel is a pioneering female inventor based in Paris, France, known for her groundbreaking contributions to the field of medical research and immunotherapy.

Latest Patents: Laurence Zitvogel holds several patents related to novel cancer treatment methods utilizing the body's immune system to target and destroy cancer cells effectively.

Career Highlights: With a distinguished career in oncology and immunotherapy, Laurence Zitvogel has been at the forefront of developing innovative approaches to cancer treatment, focusing on personalized medicine and immunological interventions.

Collaborations: Throughout her career, Laurence Zitvogel has collaborated with leading researchers, pharmaceutical companies, and medical institutions worldwide to further advance the field of immunotherapy and cancer research.

Conclusion: Laurence Zitvogel's dedication to pushing the boundaries of medical science and her relentless pursuit of innovative solutions have solidified her reputation as a trailblazing inventor in the field of oncology and immunotherapy.

This text is generated by artificial intelligence and may not be accurate.